Compare · CHPT vs EW
CHPT vs EW
Side-by-side comparison of ChargePoint Holdings Inc. (CHPT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- CHPT operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $52.38B, about 346.3x CHPT ($151.2M).
- Over the past year, CHPT is down 49.6% and EW is up 11.7% - EW leads by 61.3 points.
- Both names hit the wire about 3 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- ChargePoint Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- $5.83-1.69%
- $90.83+0.31%
- Market cap
- $151.2M
- $52.38B
- 1M return
- +7.76%
- +9.41%
- 1Y return
- -49.57%
- +11.74%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 3
- 3
- Recent ratings
- 25
- 25
ChargePoint Holdings Inc.
ChargePoint Holdings, Inc. provides electric vehicle (EV) charging networks and charging solutions in the United States. It offers a portfolio of hardware, software, and services for commercial, fleet, and residential customers. The company was founded in 2007 and is headquartered in Campbell, California.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest CHPT
- ChargePoint to Announce Second Quarter Fiscal Year 2027 Financial Results on September 2, 2026
- ChargePoint and Portland International Airport Set New Standard for Rental Car Electrification with Industry-Leading Overhead Fast Charging
- ChargePoint and Mercedes-Benz Partner to Simplify Fleet Electrification with End-to-End Charging Solutions
- ChargePoint Holdings Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure
- Director Singh-Bushell Ekta was granted 25,050 shares, increasing direct ownership by 122% to 45,627 units (SEC Form 4)
- Director Heystee Susan was granted 25,050 shares, increasing direct ownership by 120% to 45,945 units (SEC Form 4)
- Director Linse Michael was granted 27,555 shares, increasing direct ownership by 129% to 48,930 units (SEC Form 4)
- Director Leschly Mark was granted 26,386 shares, increasing direct ownership by 123% to 47,761 units (SEC Form 4)
- Director Harris Jeffrey was granted 28,390 shares, increasing direct ownership by 133% to 49,765 units (SEC Form 4)
- Director Harries Axel was granted 25,050 shares, increasing direct ownership by 117% to 46,425 units (SEC Form 4)
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results